Goldman Sachs’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-2,700
| Closed | -$158K | – | 6491 |
|
|
2017
Q4 | $158K | Buy |
+2,700
| New | +$170K | ﹤0.01% | 5531 |
|
|
2017
Q3 | – | Sell |
-100
| Closed | -$12K | – | 6923 |
|
|
2017
Q2 | $12K | Sell |
100
-100
| -50% | -$11.6K | ﹤0.01% | 6637 |
|
|
2017
Q1 | $23K | Sell |
200
-700
| -78% | -$81.7K | ﹤0.01% | 6482 |
|
|
2016
Q4 | $98K | Sell |
900
-800
| -47% | -$95.3K | ﹤0.01% | 6155 |
|
|
2016
Q3 | $280K | Hold |
1,700
| – | – | ﹤0.01% | 5531 |
|
|
2016
Q2 | $243K | Hold |
1,700
| – | – | ﹤0.01% | 5531 |
|
|
2016
Q1 | $218K | Sell |
1,700
-36,800
| -96% | -$4.35M | ﹤0.01% | 5537 |
|
|
2015
Q4 | $5.75M | Buy |
38,500
+28,800
| +297% | +$4.88M | ﹤0.01% | 2700 |
|
|
2015
Q3 | $1.61M | Sell |
9,700
-8,800
| -48% | -$1.94M | ﹤0.01% | 4016 |
|
|
2015
Q2 | $4.47M | Sell |
18,500
-66,800
| -78% | -$17.8M | ﹤0.01% | 3063 |
|
|
2015
Q1 | $24.1M | Buy |
85,300
+71,600
| +523% | +$15.5M | 0.01% | 1621 |
|
|
2014
Q4 | $2.14M | Sell |
13,700
-46,700
| -77% | -$8.63M | ﹤0.01% | 3773 |
|
|
2014
Q3 | $14.3M | Sell |
60,400
-174,900
| -74% | -$44.6M | ﹤0.01% | 2067 |
|
|
2014
Q2 | $55.7M | Buy |
235,300
+200,700
| +580% | +$52.9M | 0.02% | 1015 |
|
|
2014
Q1 | $11.4M | Buy |
+34,600
| New | +$11.7M | ﹤0.01% | 2257 |
|
Goldman Sachs's ICPT Position: Q4 2023 in Review
Goldman Sachs sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 1,019,073 shares — an estimated $18.9M sold.
Goldman Sachs first reported a position in ICPT in Q1 2014 and held it in 39 quarters. The position peaked at $48.4M in Q1 2019. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- Goldman Sachs reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- Goldman Sachs sold 1,019,073 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $18.9M.
- Goldman Sachs first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2014 and held it in 39 quarters.
- Goldman Sachs's Intercept Pharmaceuticals, Inc. position peaked at $48.4M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on Goldman Sachs's 13F filing for Q4 2023, filed 13 Feb 2024.